The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells displayed moderate to strong cytoplasmic and nuclear immunoreactivity.
Moderate cytoplasmic staining, often combined with nuclear positivity, was observed in most malignancies.
A majority of renal cancers and several prostate cancers were strongly stained.
Malignant tissues displayed weak to moderate cytoplasmic immunoreactivity in most cases. Malignant carcinoids displayed moderate to strong positivity. Most squamous cell carcinoma, basal cells carcinomas and several malignant gliomas and lymphomas were negative.
Cases of prostate, renal, endometrial cancers as well as malignant lymphoma and melanoma displayed moderate to strong positivity.
Weak to moderate cytoplasmic staining often combined with nuclear positivity was observed in most malignant cells. Malignant gliomas as well as most cases in skin, testicular, lung, gastric and pancreatic cancers were negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
